Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

Abstract Background In patients with epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC), epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) treatment has shown a good response. Subsequent treatments jeopardize the ability to determine the e...

Повний опис

Бібліографічні деталі

Автори:	Hisao Imai, Kyoichi Kaira, Keita Mori, Mie Kotake, Masumi Mitani, Naoko Kawashima, Takeshi Hisada, Koichi Minato
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2019-12-01
Серія:	Thoracic Cancer
Предмети:	Advanced non‐small‐cell lung cancer EGFR mutations EGFR‐TKIs introduction overall survival post‐progression survival
Онлайн доступ:	https://doi.org/10.1111/1759-7714.13193
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!